152 related articles for article (PubMed ID: 20223478)
1. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.
Hampp C; Saidi AS; Winterstein AG
J Pediatr; 2010 Jun; 156(6):953-959.e1. PubMed ID: 20223478
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
5. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
Warren A; Langley JM; Thomas W; Scott J
Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ
Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of palivizumab prophylaxis in infants and children in Florida.
Winterstein AG; Hampp C; Saidi A
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):53-60. PubMed ID: 21919115
[TBL] [Abstract][Full Text] [Related]
12. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
13. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.
Sorrentino M; Powers T
Pediatr Infect Dis J; 2000 Nov; 19(11):1068-71. PubMed ID: 11099087
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.
Chang SG; Park MS; Yu JE
J Korean Med Sci; 2010 Feb; 25(2):251-6. PubMed ID: 20119579
[TBL] [Abstract][Full Text] [Related]
17. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
Curtiss FR; Fairman KA
J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
[No Abstract] [Full Text] [Related]
18. Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.
Bauman J; Eggleston M; Oquist N; Malinoski F
South Med J; 2007 Jul; 100(7):669-76. PubMed ID: 17639745
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]